Descubre el Año SEPAR de la Vía Aérea 2026/27 y sigue sus contenidos sobre asma, EPOC y bronquiectasias para mejorar la salud respiratoria.
Analysis of eosinophilic bronchiectasis exploring airway inflammation, blood eosinophils, microbial associations and disease severity using LC-MS/MS techniques.
Review of the treatable traits approach in bronchiectasis, exploring phenotypes, endotypes, comorbidities, and its translation into clinical practice.
Study reveals systemic immune alterations in bronchiectasis patients with chronic Pseudomonas infection, highlighting persistent immune imbalance.
Observational study shows bronchiectasis symptoms independently predict exacerbations and identify patients who benefit from macrolide therapy, even with few prior episodes.
The GREAT-2 trial shows that gremubamab significantly reduces Pseudomonas aeruginosa load and enhances quality of life in bronchiectasis patients. Discover the results now.
Discover how the Treatable Traits approach transforms the management of asthma, bronchiectasis, and COPD through personalized precision medicine strategies.
The CAAT is a standardized 8-item questionnaire to assess health status in people with asthma, COPD, and other airway diseases. Now validated beyond COPD.
Sputum metagenomics reveals pan-European variation in microbial and resistome profiles in bronchiectasis: an EMBARC-BRIDGE study.
Expertos se reúnen en el Hospital Clínic para abordar el diagnóstico y tratamiento de las bronquiectasias en una jornada de formación multidisciplinar.
